bioRxiv · 10.1101/2021.11.09.467693
The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant
Abstract
Variants of concern (VOCs) of severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) threaten the global response to the COVID-19 pandemic. The alpha (B.1.1.7) variant appeared in the UK became dominant in Europe and North America in early 2021. The Spike glycoprotein of alpha has acquired a number mutations including the P681H mutation in the polybasic cleavage site that has been suggested to enhance Spike cleavage. Here, we show that the alpha Spike protein confers a level of resistance to the effects of interferon-{beta} (IFN{beta}) in lung epithelial cells. This correlates with resistance to restriction mediated by interferon-induced transmembrane protein-2 (IFITM2) and a pronounced infection enhancement by IFITM3. Furthermore, the P681H mutation is necessary for comparative resistance to IFN{beta} in a molecularly cloned SARS-CoV-2 encoding alpha Spike. Overall, we suggest that in addition to adaptive immune escape, mutations associated with VOCs also confer replication advantage through adaptation to resist innate immunity.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lista, M. J., Winstone, H., Wilson, H., Dyer, A., Pickering, S., Galao, R. P., De Lorenzo, G., Cowton, V., Furnon, W., Suarez, N. M., Orton, R., Palmarini, M., Patel, A. H., Snell, L. B., Nebbia, G., Swanson, C. M., Neil, S.. 2021-11-10. The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant. https://doi.org/10.1101/2021.11.09.467693
Cite the original work for its findings. Save a collection to share your selection of sources.